Subscribe To
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
New analyses of sotagliflozin showing time to clinical benefit presented at the american college of cardiology’s 72nd annual scientific session together with world heart federation’s world congress of
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection f...
March 4, 2023, 5:00 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve
Results Demonstrate Significant Reductions in LDL-C, hsCRP and cardiovascular Risk in Patients Who Are ...
March 4, 2023, 3:30 pm
Keros therapeutics reports recent business highlights and fourth quarter and full year 2022 financial results
LEXINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage bio...
March 3, 2023, 9:01 pm
Verve therapeutics reports new preclinical data demonstrating potent and durable editing of angptl3 gene with verve-201 in wild-type and ldlr-deficient non-human primates
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initi...
March 3, 2023, 11:30 am
Bioabsorbable stents market to exceed us$ 560.1 mn by 2031: tmr study
Significant utilization of bioabsorbable polymer-based stents, particularly to treat coronary artery diseases, is expected to offer substantial opport...
March 2, 2023, 11:30 pm
Dream-hf phase 3 trial results for mesoblast cell therapy in heart failure published in journal of the american college of cardiology (jacc)
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the...
February 27, 2023, 11:29 pm
Windtree announces istaroxime scientific abstract has been accepted at the 2023 technology and heart failure therapeutics conference
WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnolog...
February 27, 2023, 1:00 pm
Merit medical: reasonably-priced execution, with m&a upside
Merit Medical delivered a modestly better than expected fourth quarter, with a little upside on revenue and a $0.02/share beat at the operating income...
February 25, 2023, 1:53 am
Merit medical (mmsi) q4 earnings top estimates, margins down
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in its cardiovascular segment...
February 23, 2023, 12:03 pm
Medtronic plc (mdt) q3 2023 earnings call transcript
Medtronic plc (NYSE:MDT ) Q3 2023 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Ryan Weispfenning - Investor Relations Ge...
February 21, 2023, 12:29 pm
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am